The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) (“Cronos Group” or “the Company”), has divested its equity interest in Vert/Green Medical Inc. (“Vert”). Vert was acquired by Canopy Growth Corporation (“Canopy”) in a share-for-share transaction that Canopy today announced has closed. As a result of the transaction, the Company today acquired, through …
PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) (“Cronos Group” or “the Company”), has divested its equity interest in Vert/Green Medical Inc. (“Vert”). Vert was acquired by Canopy Growth Corporation (“Canopy”) in a share-for-share transaction that Canopy today announced has closed. As a result of the transaction, the Company today acquired, through its wholly-owned subsidiary Hortican Inc., 7,374 shares of Canopy and may acquire up to 29,498 additional shares of Canopy subject to escrow conditions relating to certain licensing milestones for Vert.
Canopy has announced that as part of the transaction it will immediately repay Vert’s debt, which includes the $422,933.45 currently owed to Cronos Group.
“As we concentrate on optimizing and expanding our wholly-owned subsidiaries – Peace Naturals Project Inc. and In The Zone Produce Inc., we welcome the opportunity to monetize non-core assets,” said Cronos Group CEO Mike Gorenstein. “This transaction allows us to secure non-dilutive capital to further develop our core assets.”
About Cronos Group
PharmaCan Capital Corp., known as the Cronos Group, is a holding company for licensed producers under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and two license applicants, Cronos Group is focused on building iconic brands providing patients with compassionate, personalized care.
The Peace Naturals Project Inc., a wholly-owned subsidiary of the Company, is licensed to produce up to 2,500 kg of medical marijuana per year and is located on 95-acres of land in Ontario. Peace has current grow facilities of approximately 38,000 square feet.
The Company’s other wholly-owned subsidiary, In the Zone Produce Inc., is licensed to produce up to 100 kg of medical marijuana per year and is located on 31 acres of land in the Okanagan Valley, BC.
The Company also has stakes in: Whistler Medical Marijuana Corporation, ABcann Medicinals Inc., Hydropothecary, Evergreen, and Cannmart.
For more information, please visit www.TheCronosGroup.com.
Forward-looking statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Canopy has announced that as part of the transaction it will immediately repay Vert’s debt, which includes the $422,933.45 currently owed to Cronos Group.
“As we concentrate on optimizing and expanding our wholly-owned subsidiaries – Peace Naturals Project Inc. and In The Zone Produce Inc., we welcome the opportunity to monetize non-core assets,” said Cronos Group CEO Mike Gorenstein. “This transaction allows us to secure non-dilutive capital to further develop our core assets.”
About Cronos Group
PharmaCan Capital Corp., known as the Cronos Group, is a holding company for licensed producers under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and two license applicants, Cronos Group is focused on building iconic brands providing patients with compassionate, personalized care.
The Peace Naturals Project Inc., a wholly-owned subsidiary of the Company, is licensed to produce up to 2,500 kg of medical marijuana per year and is located on 95-acres of land in Ontario. Peace has current grow facilities of approximately 38,000 square feet.
The Company’s other wholly-owned subsidiary, In the Zone Produce Inc., is licensed to produce up to 100 kg of medical marijuana per year and is located on 31 acres of land in the Okanagan Valley, BC.
The Company also has stakes in: Whistler Medical Marijuana Corporation, ABcann Medicinals Inc., Hydropothecary, Evergreen, and Cannmart.
For more information, please visit www.TheCronosGroup.com.
Forward-looking statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information
Michael Krestell
Investor & Media Relations
TEL: (416) 603-7381 EXT #236
E-mail: michael@thecronosgroup.com
Investor & Media Relations
TEL: (416) 603-7381 EXT #236
E-mail: michael@thecronosgroup.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.